Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.4MCash on Hand
1.5mo Cash Runway
Follow VNRX by emailGet an email when VNRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VNRX, unsubscribe in one click. Privacy
📣 What VNRX Says Is Next
this quarter · “We currently expect to submit this quarter.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Leadership CEO Cameron Reynolds agreed to a further temporary salary cut, from $355,456 to $236,970.50 effective November 1, 2026, with no added equity. Severance and pension remain based on his full $473,941 salary. Form 8-K · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 revenue of $1.6 million, up 157% from $0.6 million, and an operating loss of $3.3 million, narrowed from $5.1 million. Net loss was $3.8 million. Cash totaled $2.4 million at September 30, 2026, and the $7.5 million convertible note was prepaid in cash. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 27, 2026 ·
Financing VolitionRx made a $500,000 cash prepayment on its $2.4 million Lind convertible note, cutting the remaining balance to $706,667. Lind agreed not to convert until January 1, 2027 unless the stock closes at or above $0.275, and deferred the November and December 2026 repayments. Form 8-K · SEC filing · Press release
Sep 25, 2026 ·
Financing Lind Global Asset Management XII received 698,113 shares for a $185,000 note conversion on September 18, 2026, and 1,459,227 shares for a $340,000 conversion on September 23, 2026, under a $2,400,000 senior secured convertible note. Form 8-K · SEC filing
Sep 15, 2026 ·
Financing Lind Global received 706,214 shares on Sep 2, 2026 for a $250,000 note conversion and 707,236 shares on Sep 10, 2026 for a $215,000 conversion. As of Sep 14, 2026, 27,903,326 shares were outstanding. Form 8-K · SEC filing
Sep 14, 2026 ·
Financing Prepaid the remaining $422,000 principal on its $7.5 million note to Lind, with no further amounts outstanding under that note. A $2,041,667 note issued to Lind in January 2026 remains outstanding. Form 8-K · SEC filing · Press release
Sep 2, 2026 ·
Financing Lind Global consented to VolitionRx's at-the-market share sales above the $10 million annual cap, waiving related default and remedy rights and conversion and exercise price adjustments for sales after August 28, 2026. Conversion and exercise prices were adjusted for sales through that date. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
VNRX holds $2.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.9M/quarter from operations,
an estimated runway of 1.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 2 months +40
ATM program on file since Oct 2025 +15
Shelf registration (S-3, Nov 2024) +10
Going-concern doubt in the latest 10-Q +15For these reasons, our auditors included in their report on our audited financial statements for the year ended December 31, 2025, an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern.10-Q, Nov 2026
Share count 36,082,903 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full VNRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VNRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.